Dacheng Assists Guangdong Traditional Chinese Medicine Healthcare Fund in Completing Investment in New Radiomedicine

Chengdu New Radiomedicine Technology Co., Ltd. (hereinafter referred to as “New Radiomedicine”) recently completed its Series D financing of approximately RMB 800 million. The round was jointly funded by Guangdong Traditional Chinese Medicine Healthcare Fund, other renowned investment institutions and existing shareholders.

New Radiomedicine is a pioneer in the research, development and production of medical radionuclides in China. Founded in 2016, the company devotes itself to the innovative R&D, production and sales of isotopes and pharmaceutical products. Adhering to the corporate philosophy of “Nuclear Energy for the Benefit of Society”, it commits to driving innovation and development of the nuclear medicine industry. The company has multiple innovative products under development, including Yttrium [90Y] Carbon Microspheres Injection and radionuclide-conjugated monoclonal antibodies and polypeptides, which are mainly applied to the diagnosis and treatment of prevalent cancers such as liver cancer, pancreatic cancer, lymphoma, thyroid cancer, prostate cancer and lung cancer. It has built a world-class base for the R&D, production and service of medical isotopes and pharmaceuticals. Through strategic cooperation with global pharmaceutical and medical device enterprises, New Radiomedicine accelerates the localized production and operation of cutting-edge radiopharmaceuticals, striving to deliver high-quality medical solutions for patients at home and abroad.

Guangdong Traditional Chinese Medicine Healthcare Fund was jointly established by Guangdong Hengjian Investment Holdings Co., Ltd. and China Development Bank Capital Co., Ltd., with an overall scale of RMB 30 billion and an initial fundraising scale of RMB 5 billion. The fund focuses on investment in traditional Chinese medicine and healthcare sectors, targets weak links in the industrial chain, supports industrial upgrading and promotes the sound development of the traditional Chinese medicine and healthcare industry.

Dacheng Law Offices provided full legal services for Guangdong Traditional Chinese Medicine Healthcare Fund throughout the investment process. The project team consists of Guo Qing (Senior Partner), Liu Tianjiao (Partner), Zhao Liyang (Partner, pending filing), Yuan Ruixian (Associate) and Zeng Shiyuan (Associate).